Showing results (631-640 of 4,512) with videos related to
Sort By:
Pageof 452
Future Oncology (London, England)|December 5, 2014
miRNA detection methods and clinical implications in lung cancerMarta Usó, Eloisa Jantus-Lewintre, Rafael Sirera, et al.Future Oncology (London, England)|November 12, 2014
Enhancing cancer care in areas of limited resources: our next stepsNagi S El Saghir, Rania A Farhat, Raghid N Charara, et al.Future Oncology (London, England)|November 12, 2014
Therapeutic approaches in patients with newly diagnosed follicular lymphomaDavid Aguiar-Bujanda, María Jesús Blanco-Sánchez, Pedro Jiménez-Gallego, et al.Future Oncology (London, England)|January 17, 2020
Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategyPaula Chu, Sarah Batson, Matthew Hodgson, et al.Future Oncology (London, England)|January 18, 2020
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinomaMichael R Migden, Sunandana Chandra, Guilherme Rabinowits, et al.Future Oncology (London, England)|November 9, 2020
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050Jean Paty, Rickard Sandin, Arlene Reisman, et al.Future Oncology (London, England)|November 10, 2020
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, et al.Future Oncology (London, England)|September 2, 2020
The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic reviewShouki Bazarbashi, Abdullah Alsharm, Faisal Azam, et al.Future Oncology (London, England)|November 2, 2020
Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapyDeeksha G Lahori, Pegah VaraminiFuture Oncology (London, England)|February 19, 2020
Metabolic changes and interaction of tumor cell, myeloid-derived suppressor cell and T cell in hypoxic microenvironmentXiantu Ou, Weibiao LvPageof 452